| 0.3291 0.001 (0.22%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.38 | 1-year : | 0.45 |
| Resists | First : | 0.32 | Second : | 0.38 |
| Pivot price | 0.32  |
|||
| Supports | First : | 0.32 |
Second : | 0.31 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.32 |
| MA(100) : | 0.46 |
MA(250) : | 0.74 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.9 |
D(3) : | 90.9 |
| RSI | RSI(14): 62.7 | |||
| 52-week | High : | 1.55 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLK ] has closed below upper band by 19.5%. Bollinger Bands are 98.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.33 - 0.33 | 0.33 - 0.33 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.33 - 0.33 | 0.33 - 0.33 |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Tue, 10 Jun 2025
ALLK - Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - mx.advfn.com
Thu, 15 May 2025
Allakos Completes Merger with Concentra Biosciences - TipRanks
Thu, 15 May 2025
Allakos completes merger with Concentra Biosciences - Investing.com
Wed, 02 Apr 2025
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Wed, 02 Apr 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK - PR Newswire
Wed, 02 Apr 2025
Allakos stock surges on reverse merger deal (ALLK:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 76.7 (%) |
| Shares Short | 338 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -88.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|